New research suggests that a commonly prescribed class of migraine drugs may also be useful in treating obesity.
Mice taking triptan migraine drugs ate less and lost more weight than other animals.
A commonly prescribed class of migraine drugs, triptans, may also be effective in treating obesity, according to a new study by scientists at UT Southwestern. In experiments on obese mice, a daily dose of a triptan led animals to eat less food and lose weight over the course of a month, the team reported on July 7 in the Journal of Experimental Medicine.
“We’ve shown that there is real potential to repurpose these drugs, which are already known to be safe, for appetite suppression and weight loss,” said study leader Chen Liu, Ph.D., Assistant Professor of Internal Medicine and Neuroscience and an investigator in the Peter O’Donnell Jr. Brain Institute.
“We found that these drugs, and one in particular, can lower body weight and improve glucose metabolism in less than a month, which is pretty impressive.” — Chen Liu, Ph.D.
Obesity, which affects more than 41% of all adults in the U.S., is a huge health problem and increases the risk of heart disease, diabetes, stroke, and certain types of cancer. Currently, most treatments for obesity focus on eating habits and physical activity.
For a long time scientists have known that serotonin, a chemical messenger found throughout the brain and body, plays a key role in appetite. However, there are 15 different serotonin receptors – molecules that sense serotonin and signal for cells to change their behavior in response. Researchers have struggled to understand the role of each serotonin receptor in appetite, and previous drugs – including fen-phen and lorcaserin (Belviq) – that targeted certain individual receptors have been withdrawn from the market due to side effects.
Triptans, which are used to treat acute migraines and cluster headaches, work by targeting a different receptor – the serotonin 1B receptor (Htr1b) – that had not previously been well studied in the context of appetite and weight loss, said Dr. Liu.
For the new study, the scientists tested six prescription triptans in obese mice that were fed a high-fat diet for seven weeks. Mice fed two of these drugs ate about the same amount, but mice fed the other four ate less. After 24 days, mice given a daily dose of the drug frovatriptan lost, on average, 3.6% of their body weight, while mice not given a triptan gained an average of 5.1% of their body weight. Dr. Liu and his colleagues saw similar results when they implanted devices into the animals that gave them a steady dose of frovatriptan for 24 days.
“We found that these drugs, and one in particular, can lower body weight and improve glucose metabolism in less than a month, which is pretty impressive,” said Dr. Liu.
Since triptans are generally prescribed for short-term use during migraines, Dr. Liu suspects that patients would not have noticed the longer-term impacts on appetite and weight in the past.
To determine exactly how frovatriptan impacts food intake and weight, the researchers engineered mice to lack either Htr1b or Htr2c, the serotonin receptor targeted by fen-phen and lorcaserin. In mice without Htr1b, frovatriptan no longer could decrease appetite or cause weight loss, while cutting out Htr2c had no effect. This confirmed that the drug worked by targeting the serotonin 1B receptor.
“This finding could be important for drug development,” said Dr. Liu. “We not only shed light on the potential to repurpose existing triptans but also brought attention to Htr1b as a candidate to treat obesity and regulate food intake.”
The team went on to show exactly which neurons in the brain were most important for the role of Htr1b in mediating appetite, homing in on a small group of cells within the brain’s hypothalamus.
Reference: “Delineating a serotonin 1B receptor circuit for appetite suppression in mice” by Li Li, Steven C. Wyler, Luis A. León-Mercado, Baijie Xu, Youjin Oh, Swati, Xiameng Chen, Rong Wan, Amanda G. Arnold, Lin Jia, Guanlin Wang, Katherine Nautiyal, René Hen, Jong-Woo Sohn and Chen Liu, 7 July 2022, Journal of Experimental Medicine.
DOI: 10.1084/jem.20212307
Other researchers who contributed to this study include Li Li, Steven C. Wyler, Luis A. León-Mercado, Baijie Xu, Swati, Xiameng Chen, Rong Wan, and Amanda G. Arnold of UT Southwestern; Youjin Oh and Jong-Woo Sohn of Korea Advanced Institute of Science and Technology; Lin Jia of UT Dallas; Guanlin Wang of the University of Oxford; Katherine Nautiyal of Dartmouth College; and René Hen of Columbia University.
The study was funded by the National Institutes of Health (R01 DK114036, DK130892, F32DK116427, K01AA024809), the American Health Association (16SDG27260001), a UTSW Pilot and Feasibility Award, and a Grossman Endowment Award for Excellence in Diabetes Research.